Reuters logo
BRIEF-Amgen, Allergan announce FDA advisory committee meeting to review ABP 215
June 7, 2017 / 1:30 PM / 6 months ago

BRIEF-Amgen, Allergan announce FDA advisory committee meeting to review ABP 215

June 7 (Reuters) - Amgen Inc:

* Amgen and Allergan announce fda advisory committee meeting to review ABP 215, a biosimilar candidate to bevacizumab

* U.S. Fda’s oncologic drugs advisory committee will review data supporting biologics license application for abp 215 on July 13

* FDA has set a biosimilar user fee act (bsufa) target action date of Sept. 14, 2017, for ABP 215 Source text for Eikon: Further company coverage:

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below